Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Jordan Dufee

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

Back on an important level

Strategy published on 07/18/2017 | 09:16
long trade
Stop-loss triggered
Entry price : 83.78€ | Target : 88.6€ | Stop-loss : 82.1€ | Potential : 5.75%
The recent downward movement has sent Sanofi shares back to attractive levels situated around 82.36 EUR. This zone could put an end to the downward movement and offers a good timing for new long positions.
Investors have an opportunity to buy the stock and target the € 88.6.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • With a P/E ratio at 13.44 for the current year and 17.42 for next year, earnings multiples are highly attractive compared with competitors.
  • The company is one of the best yield companies with high dividend expectations.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 78.51 EUR

Weaknesses
  • The company's earnings releases usually do not meet expectations.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2017 36 177 M
EBIT 2017 9 601 M
Net income 2017 8 158 M
Debt 2017 4 345 M
Yield 2017 3,61%
P/E ratio 2017 12,85
P/E ratio 2018 17,48
EV / Sales 2017 3,05x
EV / Sales 2018 2,97x
Capitalization 106 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart SANOFI
Duration : Period : Day
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Duration : Period : Week
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders